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A b s t r a c t
Introduction: Few studies have assessed the development of transcatheter aortic valve implantation (TAVI) in Poland since its 
introduction in 2008, and data on current TAVI activity or practice are missing.
Aim: To assess the dynamics of TAVI adoption in Poland and to detect differences among Polish centres in TAVI practice and 
decision-making.
Material and methods: The Polish Interventional Cardiology TAVI Survey (PICTS) was approved by the Polish Association of 
Cardiovascular Interventions and presented to all 21 national TAVI centres. Between 2008 and 2015 the cumulative number of TAVI 
performed in Poland was 2189. The annual number of TAVI rose from 8 in 2008 to 670 in 2015 (0.21 to 17.4 implants per million 
inhabitants, respectively). 
Results: The median TAVI experience per centre was 80 procedures (95% CI: 38.1–154.6). In 2015 the TAVI penetration rate 
reached 5.12% of the estimated eligible Polish population. Inoperable and high-risk patients are treated with TAVI in all centres, 
with 52% of Heart Teams also qualifying medium-risk patients. The rate of transfemoral implantations increased to 83.2% of all 
procedures in 2015, while transapical implantations decreased to 12%. The frequency of subclavian, direct aortic or transcarotid 
routes in 2015 was below 3% each.
Conclusions: The PICTS survey observed a positive but slow rate of adoption of TAVI in Poland. When compared to Western Europe-
an countries, our findings highlight a significant treatment gap in high or prohibitive surgical risk patients with severe aortic stenosis. Re-
markable variations in TAVI practices among Polish TAVI centres warrant publication of joint national guidelines and recommendations.
Key words: heart failure, transcatheter aortic valve implantation, transcatheter aortic valve replacement, aortic valve stenosis, 
Heart Team, aortic valve regurgitation.
Introduction
Since the first-in-man procedure performed in 2002, 
transcatheter aortic valve implantation (TAVI) has be-
come the treatment of choice for inoperable patients 
and an alternative for high-risk patients with severe, 
symptomatic aortic stenosis [1, 2]. However, variations 
in regulatory, economic and social circumstances, as well 
as disease prevalence, influenced the disparity in TAVI 
adoption and practice in European countries [3]. So far, 
few studies have assessed TAVI development in Poland, 
and there is a paucity of data on TAVI activity and prac-
tice in the countries of Central and Eastern Europe [3–5]. 
The Association of Cardiovascular Intervention of the 
Polish Cardiac Society (ACVI) sought to address this gap 
by assessing the progress and current status of TAVI in 
Poland through a national web-based survey. 
Aim
Specific aims of the study were to analyse dynamics 
of TAVI adoption in Poland since its introduction in 2008 
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and to detect differences among Polish centres in prac-
tice and decision-making in percutaneous aortic valve 
therapy. 
Material and methods
Data sourcing
The survey was designed to investigate TAVI activi-
ty and practices in Polish interventional cardiology cen-
tres. It consisted of 41 single and multiple-choice ques-
tions focused on the following topics: 1. characteristics 
of centres involved in the TAVI programme in Poland; 
2. the annual number of TAVI implants from 2008 to 2015; 
3. practice of pre-, intra- and post-procedural patient 
management. It was obligatory to answer all questions 
with the possibility to comment on any of them. After ap-
proval of the questionnaire by the ACVI in January 2016, 
the survey was published online at the ACVI official web-
site, and formal invitations were sent to all invasive car-
diology centres involved in the TAVI programme in Poland 
to participate. Responses were collected electronically by 
the end of February 2016. 
Transcatheter aortic valve implantation 
penetration
We determined TAVI penetration rate as a measure of 
TAVI use relative to its use in patients with symptomatic 
severe aortic stenosis at high or excessive surgical risk 
that could potentially be treated with TAVI [6]. Following 
the already published methodology, among elderly inhab-
itants aged ≥ 75 years with severe aortic stenosis (3.4%), 
75.6% were estimated to be symptomatic, 40.5% were 
deemed to be inoperable due to excessive surgical risk, 
and 5.2% were determined to be at high operative risk. 
40.3% of inoperable patients and 80% of the high-risk 
patients were deemed to be potential TAVI candidates. 
Polish Central Statistical Office reports were used to esti-
mate the size of the elderly population aged ≥ 75 years for 
TAVI penetration analysis as well as to calculate the annu-
al number of TAVI implants per million population and the 
number of TAVI centres per million population in Poland. 
The results are presented in the paper as descriptive 
statistics. 
Results
Description of centres
The TAVI programme was introduced in Poland in De-
cember 2008 and expanded across 21 centres by the end 
of 2015 (Figure 1). The number of TAVI centres per million 
population increased from 0.05 in 2008 to 0.55 in 2015. 
All of them fully participated in the survey: 15 (71%) 
university centres, 5 (24%) community hospitals and 
1 (5%) private hospital. Following recommendations of 
the European Society of Cardiology, 21 multidisciplinary 
Heart Teams involving 46 certified interventional cardi-
ologists were established in all TAVI centres [7]. The dis-
tribution of TAVI experience across centres varied wide-
ly. The median cumulative number of TAVI implants per 
centre was 80 (95% CI: 38.1–154.6). From 2008 to 2015, 
4 centres performed more than 200 (19%) procedures, 
4 centres performed between 100 and 200 procedures 
(19%), while 13 centres performed less than 100 proce-
dures (62%; Figure 2). The median number of TAVI proce-
dures per centre per annum increased from 4 in 2008 to 
24 (95% CI: 13.7–41.4) in 2015. In the last year of survey, 
5 centres performed 50–100 procedures (24%), 7 cen-
tres 20–49 procedures (33%) and 9 centres fewer than 
20 procedures (43%). 
Number of transcatheter aortic valve 
implantation procedures
Between December 2008 and December 2015 the cu-
mulative number of TAVI procedures performed in Poland 
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Figure 1. A  cumulative number of transcatheter 
aortic valve implantation (TAVI) centres and num-
ber of TAVI centres per million population in Po-
land from 2008 to 2015
Figure 2. The TAVI activity in 21 Polish centres: 
Cumulative number of TAVI procedures per centre 
during years of activity (black markers represent 
single centres, median = 80 procedures, grey line)
 TAVI centres       TAVI centres per million population
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was 2189. The annual number of implantations increased 
from 8 in 2008 to 670 in 2015. The annual procedural 
volume growth rate was positive during all years, with 
a 42.6% increase in 2015 (Figure 3). The annual number 
of TAVI procedures per million inhabitants rose from 0.21 
in 2008 to 17.4 in 2015. The annual number of TAVI im-
plants per million inhabitants aged ≥ 75 years increased 
from 3.2 in 2008 to 247.6 in 2015 (Figures 4 A and B). 
Transcatheter aortic valve implantation 
penetration in Poland
Depending on Polish Central Statistical Office reports 
we estimated the number of potential TAVI candidates 
in the years from 2008 to 2015. Based on the number 
of TAVI recipients per annum, we calculated TAVI pene-
tration rates presented in Table I. Consequently, out of 
13 076 TAVI eligible patients in 2015, 670 were treated 
with TAVI, leading to a 5.12% penetration rate in 2015.
Transcatheter aortic valve implantation  
pre-procedural management
Risk 
All Polish centres perform TAVI in inoperable and high-
risk patients (Society of Thoracic Surgeons – STS score > 8). 
Medium risk patients (STS 4–8) are qualified for TAVI 
in 10 centres (52%), while low-risk patients (STS < 4) 
are offered transcatheter treatment in 1 centre (5%).
Imaging
Multislice computed tomography (MSCT) is the im-
aging modality performed in all Polish centres to assess 
aortic valve anatomy before TAVI. In addition, tran-
soesophageal echocardiography is concomitantly used in 
the majority of hospitals (66%). Assessment of the vas-
cular access route for TAVI is based on MSCT in 95% of 
centres, with angiography alone being used in one centre 
only (5%).
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Figure 4. The TAVI procedures per annum in Poland from 2008 to 2015: A – TAVI implants per million inhabi-
tants. B – TAVI implants per million inhabitants aged ≥ 75 years
Figure 3. The TAVI procedures in Poland per annum and percentage of their annual increase
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Coronary artery disease
Coronary angiography is routinely performed in all 
centres as a part of pre-procedural planning. If patients 
are diagnosed with significant coronary artery disease, 
the strategy of preventive percutaneous coronary angio-
plasty of main vessels (PCI) is used by default in all cen-
tres. Nineteen percent of them may qualify such patients 
for simultaneous PCI during TAVI session, and only 14% 
of centres may decide on postponing PCI in such circum-
stance. After PCI with drug-eluting stent (DES), the rec-
ommended deferral of TAVI is 1 month in 71% of centres, 
3 months in 24% and 6 months in 5% of centres.
In patients with coronary artery disease scheduled 
for TAVI with a femoral approach using surgical cutdown 
or closure devices, 95% of centres allow dual antiplatelet 
therapy (DAPT) to be maintained during TAVI. In patients 
qualified for transapical access, 60% of centres allow for 
DAPT, 35% recommend aspirin only and 5% withhold an-
tiplatelet therapy on the day of the TAVI procedure. 
Transcatheter aortic valve implantation 
procedure 
Prophylactic antibiotic therapy
Routine use of periprocedural antibiotic therapy is 
advocated in 71% of centres. The remaining centres re-
serve antibiotic therapy for patients with additional in-
dications.
Anaesthesia
Local anaesthesia for TAVI is used in 62% of centres. 
Since 2008, 12.6% of patients have been treated with 
TAVI under local anaesthesia. In 2015 the rate of such 
procedures reached 20.6%.
Choice of access sites
The transfemoral route is the default TAVI option in 
all Polish centres. Transapical access implantations have 
been performed in 95% of centres, followed by direct 
aortic (62%) and subclavian routes (48%). Only 3 centres 
have performed transcarotid TAVI in the last 2 years of 
the survey (14%). The rate of transfemoral implantations 
increased to 83.4% of all procedures in 2015, while the 
use of transapical access decreased to 11.8%. The fre-
quency of the subclavian, direct aortic or transcarotid 
route for TAVI in 2015 was below 3% each (Figure 5). 
Use of closure devices 
Percutaneous closure devices are used for the trans-
femoral TAVI approach in 43% of centres. Perclose Pro-
Glide Suture-Mediated Closure Systems (Abbott Vascu-
lar, Redwood City, CA, USA) is used by 29% of centres 
and a  single Prostar XL Percutaneous Vascular Surgical 
Systems (Abbott Vascular, Redwood City, CA, USA) in 33% 
of centres. Since the beginning of the TAVI programme 
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in Poland percutaneous closure devices have been used 
in 31.6% of patients (Perclose Proglide 3.8%, Prostar XL 
27.8%). In 2015, closure devices were used in 28.1% of 
patients (Perclose Proglide 10.4%, Prostar XL 17.7%). 
Aortic balloon valvuloplasty before transcatheter 
aortic valve implantation
Sixty-seven percent of centres consider TAVI without 
the use of aortic balloon valvuloplasty. As a result, 31% of 
patients were treated with direct TAVI in 2015.
Transcatheter aortic valve implantation  
post-procedural management
Right ventricular electrode removal after 
transcatheter aortic valve implantation
In patients without evidence of new conduction sys-
tem abnormalities, 48% of centres maintain the right- 
ventricular electrode for 2 days after the TAVI procedure, 
38% remove it after 24 h and 4% discard it in the hybrid 
room. 
Double antiplatelet therapy or anticoagulation after 
transcatheter aortic valve implantation
The antithrombotic regimens prescribed after TAVI in-
clude DAPT in 81% and single antiplatelet therapy in 19% 
of centres. No centre is currently mandating oral antico-
agulation therapy for TAVI indication only. In all patients 
with standard indications for anticoagulation, a  single 
antiplatelet agent is prescribed in combination. Anti-
platelet therapy is recommended for 3 months in 56% of 
responding centres, while a 6-month regime is supported 
by 44% of them. 
Discussion
The Polish Interventional Cardiology TAVI Survey 
(PICTS) survey is the first report of TAVI adoption and 
practice in Poland since its introduction in 2008. The main 
findings are as follows: 1. The number of TAVI centres per 
million population is 0.05 with substantial variation in 
the number of TAVI implants per centre across Poland: 
the median cumulative number of TAVI implants per cen-
tre was 80 (95% CI: 38.1–154.6); 2. The annual number 
of TAVI procedures per million population increased from 
0.21 in 2008 to 17.4 in 2015; 3. TAVI remains greatly un-
derutilised with an estimated weighted penetration rate 
of 5.12% in 2015; 4. A vast majority of patients are treat-
ed with TAVI using the transfemoral route, with the rate 
of 83.4% in 2015; 5. A broad divergence of procedural 
TAVI practices exists between national centres in Poland. 
Organisation of Polish centres built around TAVI ther-
apy adheres to current guidelines and recommendations 
with Heart Teams, interventional cardiology and cardiac 
surgery departments established in all of them [7, 8]. Al-
though their number reached an average of Western Euro-
pean nations such as France, the United Kingdom and Den-
mark, the experience of Polish centres with median 24 TAVI 
performed in 2015 is below the European average of 41 
procedures in 2011 [3]. We observed substantial variation 
of TAVI implantations per centre in Poland, with 19% of 
centres performing 50–100 procedures and 33% of centres 
performing fewer than 20 implants in 2015. Eleven centres 
performed fewer than 50 procedures in total despite their 
long activity (Figure 2). The causes of such restraints were 
beyond the scope of the study. As all centres reported long 
patient waiting lists, TAVI quota and reimbursement limits 
may be the likely causes of the slow progress rate. 
Despite a positive growth of procedural volume from 
2008 to 2015, we found that the latest annual number 
of 17.1 TAVI procedures per million population in Po-
land is 10 times lower than in Germany, 3 times lower 
than in Sweden, twice as low as in Ireland and half of 
the Western European average reported in 2011 [9–11]. 
Similarly, the estimated TAVI penetration rate of 5.12% 
in Poland in 2015 is lower than in any Western European 
country except for Portugal in 2011 [3]. According to our 
estimates, the number of TAVI eligible patients in Poland 
was 13 076 in 2015. The published estimated number of 
new TAVI candidates each year in Poland, under current 
indications, was 1220 [6]. In contrast, the number of TAVI 
procedures performed in Poland in 2015 was 670. Based 
on preliminary reports, the European Association of Per-
cutaneous Interventions (EAPCI) introduced the Valve for 
Life initiative in Poland in 2015 “to enhance awareness 
concerning inequality of patient access to the lifesaving 
indications of TAVI therapy […] with the goal of increasing 
the treatment of severe valvular heart disease by 20% by 
2020” [12]. Our survey observed a 42.6% increase of TAVI 
procedures in Poland in 2015 in comparison to 2014.
Figure 5. Temporal changes of access site use 
during TAVI in Poland per annum
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Parameter 2008 2009 2010 2011 2012 2013 2014 2015
 Transcarotid 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.9
 Subclavian 0.0 0.0 6.8 5.7 4.8 3.4 1.9 1.6
 Direct aortic 0.0 0.0 1.4 1.9 12.0 12.4 7.7 2.2
 Transapical 75.0 47.3 13.7 17.1 8.8 15.0 16.4 11.8
 Transfemoral 25.0 52.7 78.1 75.4 74.4 69.1 73.8 83.4
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Patient risk distribution in Polish centres resembles 
current European practice with universal acceptance of 
TAVI in patients with extreme and high risk, but also in 
selected medium risk patients [13]. The MSCT is the im-
aging technique of choice for aortic valve and vascular 
access route assessment, reflecting current guidelines 
and concordance with European standards [8, 14, 15]. 
Coronary revascularisation procedures (PCI) in patients 
qualified for TAVI in Poland are performed before the 
procedure in all centres according to the actual Europe-
an recommendations for revascularization [16]. The ob-
served practice of PCI during TAVI used in 19% of centres 
or postponing PCI after TAVI present in 14% of centres 
may reflect the preference given to the treatment of aor-
tic stenosis and incomplete evidence for management of 
coronary artery disease before TAVI [16, 17]. Variations in 
practice of maintaining dual antiplatelet therapy before 
TAVI using the transapical approach may mirror difficult 
decision-making in high-risk patients. 
Contrary to recent reports of the German AQUA Reg-
istry of transapical use in 22.3% of patients qualified for 
TAVI, the number of Polish patients treated transapically 
decreased to 11.8% of all procedures in 2015, while the 
transfemoral approach was predominant in Poland from 
2009 onwards [10]. The factors influencing such chang-
es may be technology advances in the design of femoral 
delivery systems and supportive long-term results of TAVI 
procedures in medium-risk patients using transfemoral 
access [18]. Infrequent use of alternative access sites 
(subclavian, direct aortic, transcarotid) may have been 
limited by the facilitated transfemoral approach and rel-
atively low procedural volume in Polish centres.
The observed predominant use of surgical femoral 
artery cutdown over suture-based closure devices may 
be explained by assumed avoidance of vascular compli-
cations and bleeding as well as the decreasing cost of 
the procedure. Also, TAVI operators need thorough ex-
perience in using closure systems, which is possible to 
achieve with a high number of implantations. The report-
ed preference of Prostar XL over Proglide use in Polish 
centres depends on local practice. Current conflicting re-
ports on the safety of closure device use in TAVI suggest 
the need for further research in this field [19, 20].
The relatively large proportion of patients treated 
with direct valve implantation may represent the process 
of simplifying the TAVI procedure to increase its safety, 
but more evidence for such an approach is needed [21]. 
In fact, 33% of Polish centres perform aortic valvuloplasty 
during TAVI. 
The DAPT after TAVI is currently recommended in 
most centres, while more evidence is needed on anti-
thrombotic therapy [22]. There is a broad range of recom-
mended duration of DAPT across national centres, with 
no consensus present also in a European survey in which 
53% of centres supported a 3-month and 19% a 6-month 
DAPT after valve implantation [13].
The survey has the following limitations, which should 
be considered when interpreting the results. Although the 
study was fully addressed by all Polish TAVI centres, the 
answers were provided mostly by interventional cardiol-
ogists and may not be fully representative of the whole 
multidisciplinary team community. The numbers of TAVI 
procedures reported were not validated with registries of 
the national health system administration in the years 
2008–2013 due to the lack of such reports. The causes of 
the low TAVI penetration rate were not surveyed in the 
study and further research in this field is warranted. The 
estimates of TAVI use are likely to have included patients 
treated for off-label indications, such as patients at lower 
surgical risk, which may have affected the estimates of 
TAVI penetration. Direct comparisons to TAVI adoption 
practices in countries of Central and Eastern Europe were 
not described due to the absence of published reports. 
Conclusions
The PICTS survey highlighted a positive but relative-
ly slow rate of adoption of TAVI in Poland. When com-
pared to Western European countries, our findings point 
to a  large treatment gap in high or prohibitive surgical 
risk patients with severe aortic stenosis. In addition, re-
markable regional variations in TAVI growth exist among 
Polish TAVI centres. Currently, the EAPCI Valve for Life 
campaign addresses the problem with multidirectional 
actions aiming to offer improved care to Polish patients. 
Finally, substantial discrepancies between practices of 
centres point to the need for publication of joint national 
guidelines and recommendations. 
Impact on daily practice
Until now temporal changes of TAVI adoption and 
practice in countries of Central and Eastern Europe have 
remained largely unreported. The PICTS study highlights 
a slow rate of TAVI adoption in Poland in comparison to 
countries of Western Europe. We observed significant im-
provements of TAVI penetration after the introduction of 
the EAPCI Valve for Life campaign in Poland. The survey 
demonstrated wide variations in TAVI practice among 
Polish centres, calling for publication of joint TAVI prac-
tice guidelines.
Acknowledgments
The authors would like to thank the leaders of Pol-
ish TAVI Heart Teams for their help in providing datasets 
used in the PICTS study and their support given to the 
Valve-for-Life programme: 
•	 Sławomir Dobrzycki, Paweł Kralisz, Marek Frank, 
Tomasz Hirnle, Medical University of Białystok, 
Białystok;
•	 Paweł Buszman, Marcin Dębiński, Wojciech Doma-
radzki, Marek Cisowski, American Heart of Poland, 
Bielsko-Biała; 
Radosław Parma et al. The Polish Interventional Cardiology TAVI Survey
16 Advances in Interventional Cardiology 2017; 13, 1 (47)
•	 Wojciech Pawliszak, Dr Antoni Jurasz Memorial Uni-
versity Hospital, Bydgoszcz; 
•	 Robert Romanek, Maurycy Missima, 10th Military Re-
search Hospital, Bydgoszcz; 
•	 Dariusz Ciećwierz, Dariusz Jagielak, Medical Universi-
ty of Gdansk, Gdańsk; 
•	 Andrzej Ochała, Wojciech Wojakowski, Grzegorz 
Smolka, Radosław Parma, Marek Deja, Medical Uni-
versity of Silesia, Katowice; 
•	 Dariusz Dudek, Jarosław Trębacz, Paweł Kleczyński, 
Robert Sobczyński, Bogusław Kapelak, Jagiellonian 
University Medical College, Kraków; 
•	 Jarosław Wójcik, Andrzej Madejczyk, Janusz Stążka, 
Medical University of Lublin, Lublin; 
•	 Michał Kidawa, Bogdan Jegier, Andrzej Walczak, 
Michał Krejca, Medical University of Lodz, Łódź; 
•	 Jerzy Sacha, Jacek Kaperczak, Regional Medical 
Center, Opole; 
•	 Maciej Lesiak, Marek Grygier, Marcin Misterski, Marek 
Jemielity, Poznan University of Medical Sciences, 
Poznań; 
•	 Piotr Olszówka, Kazimierz Widenka, 2nd District Hos-
pital, Rzeszów; 
•	 Jarosław Gorący, Maciej Lewandowski, Mirosław Bryk-
czyński, Pomeranian Medical University, Szczecin;
•	 Wojciech Wąsek, Grzegorz Suwalski, Military Institute 
of Medicine, Warsaw;
•	 Robert Gil, Tomasz Pawłowski, Piotr Suwalski, Central 
Clinical Hospital of the Ministry of the Interior and 
Administration, Warsaw;
•	 Janusz Kochman, Zenon Huczek, Radosław Wilimski, 
Medical University of Warsaw, Warsaw;
•	 Adam Witkowski, Zbigniew Chmielak, Maciej Dą-
browski, Krzysztof Kuśmierski; Institute of Cardiology, 
Warsaw;
•	 Marcin Protasiewicz, Marek Jasiński, Wrocław Medi-
cal University, Wrocław;
•	 Krzysztof Reczuch, Artur Telichowski, Jacek Skiba, 
Clinical Military Hospital, Wrocław;
•	 Krzysztof Wilczek, Piotr Chodór, Marian Zembala, 
Medical University of Silesia, Zabrze;
•	 Andrzej Kleinrok, Tomasz Smyk, Łukasz Tułecki, Pope 
John Paul II Hospital, Zamość.
Footnotes
RP and MD contributed equally to this study. Study 
concept, design and supervision: all authors. Conduct of 
the study: RP, MD. Analysis and interpretation of data: 
RP, MD. Drafting and revision of the manuscript: all au-
thors. Approval of the final version of the manuscript: all 
authors.
Conflict of interest 
The authors declare no conflict of interest.
References
1. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcath-
eter implantation of an aortic valve prosthesis for calcific aortic 
stenosis. First Human Case Description 2002; 106: 3006-8.
2. Siontis GCM, Praz F, Pilgrim T, et al. Transcatheter aortic valve 
implantation vs. surgical aortic valve replacement for treatment 
of severe aortic stenosis: a meta-analysis of randomized trials. 
Eur Heart J 2016; 37: 3503-12.
3. Mylotte D, Osnabrugge RL, Windecker S, et al. Transcatheter 
aortic valve replacement in Europe: adoption trends and factors 
influencing device utilization. J Am Coll Cardiol 2013; 62: 210-9.
4. Osnabrugge RL, Kappetein AP, Reynolds MR, et al. Cost-effec-
tiveness of transcatheter valvular interventions: economic chal-
lenges. EuroIntervention 2013; 9 Suppl: S48-54.
5. Di Mario C, Eltchaninoff H, Moat NE, et al. The 2011-12 pilot Eu-
ropean Sentinel Registry of Transcatheter Aortic Valve Implan-
tation: in-hospital results in 4,571 patients. EuroIntervention 
2013; 8: 1362-71.
6. Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the 
elderly: disease prevalence and number of candidates for tran-
scatheter aortic valve replacement: a meta-analysis and model-
ing study. J Am Coll Cardiol 2013; 62: 1002-12.
7. Vahanian A, Alfieri O, Al-Attar N, et al. Transcatheter valve im-
plantation for patients with aortic stenosis: a  position state-
ment from the European Association of Cardio-Thoracic Surgery 
(EACTS) and the European Society of Cardiology (ESC), in collab-
oration with the European Association of Percutaneous Cardio-
vascular Interventions (EAPCI). Eur Heart J 2008; 29: 1463-70.
8. Tommaso CL, Bolman RM 3rd, Feldman T, et al. Multisociety 
(AATS, ACCF, SCAI, and STS) expert consensus statement: opera-
tor and institutional requirements for transcatheter valve repair 
and replacement, part 1: transcatheter aortic valve replacement. 
J Am Coll Cardiol 2012; 59: 2028-42.
9. Mylotte D, Piazza N, Serruys PW. TAVI adoption in Germany: on-
wards and upwards. EuroIntervention 2016; 11: 968-70.
10. Eggebrecht H, Mehta RH. Transcatheter aortic valve implanta-
tion (TAVI) in Germany 2008-2014: on its way to standard ther-
apy for aortic valve stenosis in the elderly? EuroIntervention 
2016; 11: 1029-33.
11. Rück A. SWEDEHEART Annual Report 2015: Percutaneous Valve 
Registry. In: Tillberg M (ed.). SWEDEHEART Annual Report 2015: 
Tomas Jernberg 2016; 298.
12. Windecker S, Haude M, Baumbach A. Introducing a new EAPCI 
programme: the valve for life initiative. EuroIntervention 2016; 
11: 977-9.
13. Petronio AS, Capranzano P, Barbato E, et al. Current status of 
transcatheter valve therapy in Europe: results from an EAPCI 
survey. EuroIntervention 2016; 12: 890-5.
14. Achenbach S, Delgado V, Hausleiter J, et al. SCCT expert consen-
sus document on computed tomography imaging before tran-
scatheter aortic valve implantation (TAVI)/transcatheter aortic 
valve replacement (TAVR). J Cardiovasc Comput Tomogr 2012; 
6: 366-80.
15. Dill KE, George E, Abbara S, et al. ACR appropriateness criteria 
imaging for transcatheter aortic valve replacement. J Am Coll 
Radiol 2013; 10: 957-65.
16. Abramowitz Y, Banai S, Katz G, et al. Comparison of early and 
late outcomes of TAVI alone compared to TAVI plus PCI in aor-
tic stenosis patients with and without coronary artery disease. 
Catheter Cardiovasc Interv 2014; 83: 649-54.
Radosław Parma et al. The Polish Interventional Cardiology TAVI Survey
17Advances in Interventional Cardiology 2017; 13, 1 (47)
17. Gasparetto V, Fraccaro C, Tarantini G, et al. Safety and effective-
ness of a selective strategy for coronary artery revascularization 
before transcatheter aortic valve implantation. Catheter Cardio-
vasc Interv 2013; 81: 376-83.
18. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical 
aortic-valve replacement in intermediate-risk patients. N Engl 
J Med 2016; 374: 1609-20.
19. Barbanti M, Capranzano P, Ohno Y, et al. Comparison of su-
ture-based vascular closure devices in transfemoral transcathe-
ter aortic valve implantation. EuroIntervention 2015; 11: 690-7.
20. Barbash IM, Barbanti M, Webb J, et al. Comparison of vascular 
closure devices for access site closure after transfemoral aortic 
valve implantation. Eur Heart J 2015; 36: 3370-9.
21. Bijuklic K, Haselbach T, Witt J, et al. Increased risk of cerebral 
embolization after implantation of a balloon-expandable aortic 
valve without prior balloon valvuloplasty. JACC Cardiovasc Interv 
2015; 8: 1608-13.
22. Gargiulo G, Collet JP, Valgimigli M. Antithrombotic therapy in 
TAVI patients: changing concepts. EuroIntervention 2015; 11: 
W92-5.
